Cambridge Respiratory Innovations Limited (CRiL) is developing a respiratory management solution based on innovative, low-cost personal medical devices that accurately measure CO2 in normal tidal breathing. CRiL’s N-Tidal Respiratory Management System (N-Tidal RMS) will transform the treatment of respiratory diseases by significantly improving diagnosis, monitoring and self-care. An advanced prototype of the most important component, the N-Tidal monitor platform, has been successfully validated in a clinical setting within Chronic Obstructive Pulmonary Disease (COPD), which will be the company’s launch respiratory condition. Other cardio-respiratory conditions that can be managed by CRiL's technology include asthma, congestive heart failure and dysfunctional breathing.
CRiL was formed in 2013 specifically to develop a respiratory management system based around innovative medical devices to diagnose and manage cardio-respiratory conditions. The N-Tidal solution is centred on a low-cost platform technology which measures and analyses tidal breathing CO2 (TBCO2) throughout the entire breath